Conformal

Morphic Medical Welcomes New Additions to Board of Directors

Retrieved on: 
Monday, November 13, 2023
General Health, Diabetes, Medical Devices, Health, Clinical Trials, Obesity, Bausch, Acquisition, Transport, Surgery, Senior, Medtronic, Risk, DSM-IV codes, Patient, Strategic planning, Medicine, Conformal, Marketing, University, GI, Instrument, Glycated hemoglobin, Operating partner, INSEAD, LivaNova, Pharmaceutical industry, Boston Scientific, Covidien

Morphic Medical , creator of the world’s first medical device designed to target the underlying cause of type 2 diabetes, today announced the addition of James Reinstein, Teresa Matterelli, and John Barr to the company’s Board of Directors.

Key Points: 
  • Morphic Medical , creator of the world’s first medical device designed to target the underlying cause of type 2 diabetes, today announced the addition of James Reinstein, Teresa Matterelli, and John Barr to the company’s Board of Directors.
  • Before joining Conformal, Mr. Reinstein served as President, CEO, and board member for several other medical device and diagnostic companies including Saranas Inc., Cutera Inc., Drawbridge Health Inc., and Aptus Endosystems.
  • “I look forward to working with Morphic Medical and making a difference in the lives of patients suffering from metabolic diseases such as diabetes and obesity,” said Ms. Mattarelli.
  • Prior, Mr. Barr served on the Board of Directors of Valeritas Holdings Inc., a medical technology company focused on the treatment of diabetes.

Conformal Medical Selected as Powerhouse MedTech Company of the Year by New England Venture Capital Association's 2023 NEVY Awards

Retrieved on: 
Tuesday, December 12, 2023
House of Blues, CLAAS, Love, LAA, Risk, Patient, House, Conformal, Atrial fibrillation, Anticoagulant, Stroke, Physician, Boston

NASHUA, N.H., Dec. 12, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today that the company was selected as the Powerhouse MedTech Company of the Year at the 11th Annual NEVY Awards .

Key Points: 
  • NASHUA, N.H., Dec. 12, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today that the company was selected as the Powerhouse MedTech Company of the Year at the 11th Annual NEVY Awards .
  • Hosted by the New England Venture Capital Association, the event celebrates the region's startup, venture backed companies, recognizing top innovators and companies in New England.
  • This year's Peace, Love, NEVY's awards were presented during the December 7th live event at the House of Blues in Boston.
  • "Conformal is honored to be selected for this prestigious award and we appreciate the New England Venture Capital Association for its continued support of companies and investors driving innovation in New England," said James Reinstein, President and CEO of Conformal Medical.

Conformal Medical Announces Compelling One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study

Retrieved on: 
Tuesday, October 24, 2023
Stroke, Atrial fibrillation, Ventricular fibrillation, Structure, Physician, Conformal, CLAAS, TEE, Anticoagulant, LAA, Risk, EFS, Safety, TCT, Patient, Main Line Health, Thomas Jefferson University, Medical device, Medicine

CLAAS® System live case presentation by Dr. Shephal Doshi on Thursday, October 26th

Key Points: 
  • CLAAS® System live case presentation by Dr. Shephal Doshi on Thursday, October 26th
    NASHUA, N.H., Oct. 24, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the positive one-year results from the company's CONFORMAL Early Feasibility Study (EFS).
  • "These results are clinically compelling and support the feasibility of the CLAAS System to safely and effectively provide durable closure for LAAO indicated patients."
  • The multi-center, single-arm, prospective study enrolled patients indicated for LAAO at 10 U.S. clinical sites.
  • Wednesday, October 25th - Conformal Medical to host a breakfast symposium, "CLAAS Act: Conformal Medical Overview and CONFORM Trial Update" at 6:30am PT in Presentation Theater 1.

Conformal Medical to Present One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study at TCT 2023

Retrieved on: 
Thursday, October 19, 2023
Stroke, Medical research, Atrial fibrillation, Ventricular fibrillation, Lankenau Institute for Medical Research, Structure, Conformal, Health, CLAAS, TEE, Anticoagulant, LAA, Risk, EFS, Safety, TCT, Patient, Main Line Health, Medical device

NASHUA, N.H., Oct. 19, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the one-year results from the company's CONFORMAL Early Feasibility Study (EFS) will be presented during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA. Dr. William Gray, System Chief, Cardiovascular Diseases at Main Line Health and professor at Lankenau Institute for Medical Research will present, "Conformal CLAAS LAAO Device EFS 1-Year TEE Follow Up" during a moderated abstract session.

Key Points: 
  • "I look forward to presenting the much anticipated one-year TEE follow up data from our initial clinical experience," stated Dr. Gray.
  • "We are extremely pleased to have the one-year Conformal EFS data presented at this year's TCT conference," commented James Reinstein, CEO of Conformal Medical.
  • Conformal Medical is currently enrolling patients in its CONFORM Pivotal Trial to support U.S. commercialization.
  • Wednesday, October 25th - Conformal Medical to host a breakfast symposium, "CLAAS Act: Conformal Medical Overview and CONFORM Trial Update" at 6:30am PT in Presentation Theater 1.

Electronic Coating Technologies to Exhibit at Upcoming SMTA Events

Retrieved on: 
Thursday, August 24, 2023
Conformal, Partnership, Electronics, Exposition, PCB, ECT, HP Business Service Management, Conference, Printed circuit board

CLIFTON PARK, N.Y., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Electronic Coating Technologies (ECT) , a leading service and distributor of protective materials and application services for the electronics industry will participate in several prominent industry events across the US.

Key Points: 
  • CLIFTON PARK, N.Y., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Electronic Coating Technologies (ECT) , a leading service and distributor of protective materials and application services for the electronics industry will participate in several prominent industry events across the US.
  • At these events, attendees can meet with ECT’s technical experts to learn more about our unmatched lead times and total solution partnership.
  • Erick Campos, Sales and Business Services Manager at ECT, expressed his enthusiasm about the upcoming events, stating, "At Electronic Coating Technologies, innovation is at the core of our mission.
  • We take pride in being at the forefront of coating technologies, and these tradeshows provide an excellent platform for us to showcase our capabilities.

Enovix Receives Purchase Order to Produce Battery Cells for U.S. Army

Retrieved on: 
Tuesday, June 27, 2023
CWB, United States Department of the Army, Silicon, Conformal, Army, Cell, Mobile phone, United States Army

FREMONT, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, today announced the progression of its U.S. Army program, with a commitment to producing commercial cells for use within U.S. Army soldier’s central power source, called the Conformal Wearable Battery (CWB).

Key Points: 
  • FREMONT, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, today announced the progression of its U.S. Army program, with a commitment to producing commercial cells for use within U.S. Army soldier’s central power source, called the Conformal Wearable Battery (CWB).
  • “This achievement is yet another proof point on our journey to scale.”
    Enovix cells will be used to build pre-production CWB packs.
  • The Enovix cell has the potential to nearly double the energy density of the current CWB cells, which could result in substantial operational advantages including longer lasting and lighter battery packs.
  • Another key advantage for the Army is Enovix BrakeFlow™ technology, a breakthrough safety system that provides an extra layer of protection inside the cell.

Enovix Delivers Custom Cells to Inventus Power and U.S. Army

Retrieved on: 
Thursday, January 5, 2023
Lithium, Army of the United States, Silicon, Architecture, Business development, Department of Defense Architecture Framework, Safety, CWB, Conformal, Army, Senior, Mobile phone, United States Army

FREMONT, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today announced it has designed, developed and delivered custom sample cells for use within U.S. Army soldiers’ central power source, called the Conformal Wearable Battery (CWB).

Key Points: 
  • FREMONT, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), the leader in the design and manufacture of next generation 3D Silicon™ Lithium-ion batteries, today announced it has designed, developed and delivered custom sample cells for use within U.S. Army soldiers’ central power source, called the Conformal Wearable Battery (CWB).
  • Created by Inventus Power, the CWB integrates into a soldier’s vest and powers vital communications and navigation equipment.
  • “We’re proud to achieve the next milestone in our work with Inventus Power on the U.S. Army program,” said Ralph Schmitt, Senior Vice President, Sales and Business Development of Enovix.
  • It was awarded in conjunction with Inventus Power, a leading provider of advanced battery and power systems that specializes in the design and manufacture of lithium-ion battery packs for both military and commercial applications.

Amprius Technologies Passes Military Performance Specification Nail Penetration Test with Unprecedented 390 Wh/kg Cell

Retrieved on: 
Tuesday, December 6, 2022
Defense, Technology, Batteries, Manufacturing, Nanotechnology, Military, Other Manufacturing, Cell, Probability, Security (finance), Army of the United States, Conformal, Partnership, 8-K, BAE Systems, NYSE, Silicon, Government, CWB, Multimedia, Risk, Burn, Temperature, Electric battery, Mobile phone, United States Army, Defense, Technology, Batteries, Manufacturing, Nanotechnology, Military, Other Manufacturing

Amprius Technologies, Inc. (Amprius) (NYSE: AMPX), a leader in ultra-high energy density lithium-ion batteries with its Silicon Nanowire Anode Platform, today announced that an independent third-party testing lab has validated Amprius 390 Wh/kg polymer electrolyte cell by successfully passing the nail penetration test per the requirements of section 4.7.4.4. of the MIL-PRF-32383 (Military Performance Specification).

Key Points: 
  • Amprius Technologies, Inc. (Amprius) (NYSE: AMPX), a leader in ultra-high energy density lithium-ion batteries with its Silicon Nanowire Anode Platform, today announced that an independent third-party testing lab has validated Amprius 390 Wh/kg polymer electrolyte cell by successfully passing the nail penetration test per the requirements of section 4.7.4.4. of the MIL-PRF-32383 (Military Performance Specification).
  • View the full release here: https://www.businesswire.com/news/home/20221206005397/en/
    Amprius Technologies Passes Military Performance Specification Nail Penetration Test with Unprecedented 390 Wh/kg Cell (Photo: Business Wire)
    The test is used to determine the feasibility of a specific product in combat scenarios.
  • When conducting the test, a 0.113-inch diameter stainless steel nail is driven through a fully charged cell at a prescribed speed.
  • The cell is deemed to have passed if there is no smoke or flame following the nail penetration.

Conformal Medical Announces Leadership Transition

Retrieved on: 
Wednesday, September 7, 2022
CEO, Technology, Safety, LAA, Twilight anesthesia, NASDAQ, Food and Drug Administration, Entrepreneurship, Anticoagulant, Epidemiology, IDE, Atrial fibrillation, Food, CLAAS, Physician, Senior, Century, Stroke, Multimedia, Boston Scientific, MD, Conference, FDA, Medtronic, Bleeding, Risk, Reinstein, Method, Conformal, Patient, Pharmaceutical industry, Medical device, Ventricular fibrillation

NASHUA, N.H., Sept. 7, 2022 /PRNewswire/ -- Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, today announced the appointment of James Reinstein as President and Chief Executive Officer. With over three decades in the medical device industry, Reinstein has served as CEO for public and private companies. He succeeds Andy Levine, who will continue to serve as an advisor to the company.

Key Points: 
  • NASHUA, N.H., Sept. 7, 2022 /PRNewswire/ -- Conformal Medical, Inc. , a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology,today announced the appointment of James Reinstein as President and Chief Executive Officer.
  • With over three decades in the medical device industry, Reinstein has served as CEO for public and private companies.
  • His experience leading private and public companies positions Conformal well as we continue to achieve important milestones and proceed forward," commented Aaron Kaplan, MD, Co-Founder and Board Chair for Conformal Medical.
  • Founded in 2016, Conformal Medical, Inc. is a medical device company developing devices to prevent stroke in patients with non-valvular Afib.

Enovix Awarded Follow-On Contract to Build Wearable Battery Cells for U.S. Army Soldiers

Retrieved on: 
Wednesday, August 10, 2022
Lithium, CWB, Electric Bond and Share Company v. Securities and Exchange Commission, Energy Independence and Security Act of 2007, Industry, Forward-looking statement, GLOBE, 3D, Technology, Securities Exchange Act of 1934, SEC, Silicon, Security (finance), GM, Army, Department, Analysis, Fire, Cell, U.S. Department of Defense Strategy for Operating in Cyberspace, Army of the United States, Program, Conformal, Architecture, Safety, EV, CTO, Financial condition report, Securities Act of 1933, Weapon, Result, Entrepreneurship, Mobile phone, Electric battery, United States Army

Soldiers in the field need reliable, lightweight and long-lasting batteries and were thrilled Enovix has been chosen to demonstrate the advantages of our domestically-manufactured technology.

Key Points: 
  • Soldiers in the field need reliable, lightweight and long-lasting batteries and were thrilled Enovix has been chosen to demonstrate the advantages of our domestically-manufactured technology.
  • Safety is a top priority at Inventus Power and when we tested the Enovix battery cells with its BrakeFlow technology, the results were impressive, said Chris Turner, CTO of Inventus Power.
  • We look forward to collaborating with the company on this program, to provide an even more resilient, high-energy battery to the U.S. Army.
  • Another key advantage for the Army is BrakeFlowtechnology, a breakthrough in battery safety, made possible due to the companys unique battery architecture.